Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q4 2023 vs. Q3 2023
How the institutions holding Lakefront Biotherapeutics NV changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 73 | 88 | +15 |
| Shares | 19.2M | 19.8M | +619.2K (+3.2%) |
| Value | $662.4M | $804.5M | +$142.1M (+21.5%) |
New holders (20)
Institutions that held Lakefront Biotherapeutics NV at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 622,112 | $25.3M | 0.47% |
| Vestal Point Capital, LP | 130,000 | $5.28M | 0.56% |
| Optiver Holding B.V. | 49,960 | $2.03M | 0.06% |
| Jane Street Group, LLC | 42,682 | $1.74M | 0.00% |
| Old Mission Capital LLC | 33,980 | $1.38M | 0.04% |
| Erste Asset Management GmbH | 14,000 | $569.9K | 0.01% |
| Walleye Capital LLC | 8,998 | $365.8K | 0.01% |
| GTS Securities LLC | 8,563 | $348.1K | 0.01% |
| Deutsche Bank AG | 4,095 | $166.5K | 0.00% |
| Barometer Capital Management Inc. | 3,000 | $122.0K | 0.03% |
| GAMMA Investing LLC | 1,161 | $43.6K | 0.01% |
| Parallel Advisors, LLC | 400 | $16.3K | 0.00% |
| Cutler Group LP | 345 | $14.0K | 0.00% |
| Point72 Hong Kong Ltd | 300 | $12.2K | 0.00% |
| Lazard Asset Management LLC | 173 | $6.00K | 0.00% |
| Planned Solutions, Inc. | 100 | $4.07K | 0.00% |
| WealthCollab, LLC | 100 | $4.07K | 0.00% |
| Ronald Blue Trust, Inc. | 106 | $4.00K | 0.00% |
| Headlands Technologies LLC | 75 | $3.05K | 0.00% |
| Northwestern Mutual Wealth Management Co | 10 | $407 | 0.00% |
Sold out (5)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Tang Capital Management LLC | 89,650 | $3.10M |
| Carlson Capital L P | 25,000 | $863.8K |
| UBS Oconnor LLC | 10,888 | $376.2K |
| Barclays PLC | 6,200 | $214.2K |
| Wells Fargo & Company | 192 | $6.63K |